Sunesis Pharmaceuticals Inc., of South San Francisco, closed its underwritten offerings of about 5.6 million shares of its common stock at a price of $3.85 per share, including the exercise in full of the underwriters' option to purchase additional shares at the public offering price, and 1,558 shares of its nonvoting series C convertible preferred stock at $3,850 per share.